Meeder Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.3M Buy
79,562
+9,584
+14% +$2.13M 0.99% 22
2025
Q4
$16M Buy
69,978
+15,487
+28% +$3.53M 0.86% 24
2025
Q3
$12.6M Sell
54,491
-25,040
-31% -$5.1M 0.72% 38
2025
Q2
$14.8M Buy
79,531
+28,584
+56% +$5.31M 0.91% 23
2025
Q1
$10.7M Buy
50,947
+39,576
+348% +$7.69M 0.72% 31
2024
Q4
$2.02M Sell
11,371
-170,839
-94% -$31.4M 0.14% 81
2024
Q3
$36M Buy
182,210
+69,593
+62% +$13M 2.4% 10
2024
Q2
$19.3M Buy
112,617
+85,928
+322% +$14.2M 1.35% 19
2024
Q1
$4.86M Sell
26,689
-115,815
-81% -$20M 0.31% 75
2023
Q4
$22.1M Buy
142,504
+139,313
+4,366% +$20.3M 1.72% 7
2023
Q3
$476K Sell
3,191
-87,656
-96% -$12.9M 0.04% 187
2023
Q2
$12.2M Buy
90,847
+1,339
+1% +$196K 0.89% 23
2023
Q1
$14.3M Buy
89,508
+33,924
+61% +$5.19M 1.14% 21
2022
Q4
$8.98M Sell
55,584
-55,431
-50% -$8.5M 0.79% 22
2022
Q3
$14.9M Buy
111,015
+259
+0.2% +$37.2K 0.86% 23
2022
Q2
$17M Sell
110,756
-23,784
-18% -$3.63M 0.98% 19
2022
Q1
$21.8M Buy
+134,540
New +$19.5M 1.06% 17
2021
Q4
Sell
-127,197
Closed -$13.7M 1086
2021
Q3
$13.7M Sell
127,197
-704
-0.6% -$80.4K 0.72% 27
2021
Q2
$14.4M Buy
127,901
+3,360
+3% +$378K 0.67% 30
2021
Q1
$13.5M Buy
124,541
+107,096
+614% +$11.5M 0.69% 28
2020
Q4
$1.87M Sell
17,445
-105,030
-86% -$10.1M 0.41% 46
2020
Q3
$10.7M Buy
122,475
+697
+0.6% +$65.6K 0.69% 27
2020
Q2
$12M Buy
121,778
+21,867
+22% +$1.93M 0.78% 23
2020
Q1
$7.61M Buy
99,911
+2,865
+3% +$244K 0.59% 33
2019
Q4
$8.59M Buy
97,046
+26,516
+38% +$2.2M 0.52% 55
2019
Q3
$5.34M Buy
70,530
+10,484
+17% +$719K 0.36% 80
2019
Q2
$4.37M Buy
60,046
+12,154
+25% +$955K 0.3% 86
2019
Q1
$3.86M Buy
47,892
+4,759
+11% +$389K 0.3% 87
2018
Q4
$3.98M Sell
43,133
-6,358
-13% -$559K 0.35% 72
2018
Q3
$4.68M Sell
49,491
-18,808
-28% -$1.78M 0.35% 80
2018
Q2
$6.33M Buy
68,299
+13,519
+25% +$1.32M 0.55% 50
2018
Q1
$5.18M Sell
54,780
-3,491
-6% -$383K 0.48% 51
2017
Q4
$5.64M Buy
58,271
+2,405
+4% +$227K 0.48% 42
2017
Q3
$4.96M Sell
55,866
-30,161
-35% -$2.3M 0.54% 46
2017
Q2
$6.24M Sell
86,027
-31,496
-27% -$2.12M 0.59% 33
2017
Q1
$7.66M Buy
117,523
+19,705
+20% +$1.24M 0.69% 30
2016
Q4
$6.13M Sell
97,818
-68
-0.1% -$4.15K 0.59% 39
2016
Q3
$6.17M Buy
97,886
+46,693
+91% +$3.02M 0.52% 32
2016
Q2
$3.17M Buy
51,193
+2,453
+5% +$149K 0.3% 63
2016
Q1
$2.78M Buy
48,740
+45,209
+1,280% +$2.52M 0.26% 84
2015
Q4
$208K Sell
3,531
-20,802
-85% -$1.2M 0.02% 507
2015
Q3
$1.32M Sell
24,333
-21,484
-47% -$1.4M 0.13% 172
2015
Q2
$3.08M Buy
45,817
+2,702
+6% +$176K 0.31% 69
2015
Q1
$2.52M Hold
43,115
0.27% 98
2014
Q4
$2.82M Buy
+43,115
New +$2.72M 0.36% 86
2014
Q2
Sell
-64,815
Closed -$3.33M 336
2014
Q1
$3.33M Hold
64,815
0.55% 59
2013
Q4
$3.42M Buy
+64,815
New +$3.19M 0.58% 52

Other funds holding ABBV

Meeder Asset Management's ABBV Position: Q1 2026 in Review

Meeder Asset Management increased its AbbVie (ABBV) stake by 14% in Q1 2026, buying an estimated $2.13M and bringing the position to 79,562 shares worth $17.3M. The position accounts for 0.99% of the portfolio, ranked #22.

Meeder Asset Management first reported a position in ABBV in Q4 2013 and has held it in 47 quarters since. The position peaked at $36M in Q3 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Meeder Asset Management held 79,562 shares of AbbVie worth $17.3M as of Q1 2026.
  • Meeder Asset Management bought 9,584 AbbVie shares in Q1 2026, an estimated $2.13M.
  • AbbVie made up 0.99% of Meeder Asset Management's portfolio in Q1 2026, its #22 holding.
  • Meeder Asset Management first reported a position in AbbVie in Q4 2013 and has held it in 47 quarters since.
  • Meeder Asset Management's AbbVie position peaked at $36M in Q3 2024.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.